secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0001193125-25-056725
Event type: other_material
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.01, 9.01, 5.02, 2.02, 5.01, 5.03, 5.06, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir completes reverse merger with Legacy Kalaris; ticker changes to KLRS on Nasdaq
--------------------------------------------------------------------------------

- Post-merger combined company focuses on retinal disease therapeutics; TH103 is lead candidate.
- Legacy Kalaris securityholders own 74.47% of combined company; ~18.7M shares outstanding.
- Samsara BioCapital LP holds 61.19% of shares post-merger; new board and officers appointed.
- Ticker changes from ALVR to KLRS on Nasdaq Global Market effective March 19, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/0001193125-25-056725-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-056725

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer